Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681184 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
A Phase 3 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT03681184 is a Phase 3 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT03681184, a Phase 3 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
Interventions
- DRUG Placebo
- DRUG Lumasiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2024-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681184
The ClinicalTrials.gov registry entry for NCT03681184 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03681184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03681184 about?
NCT03681184 is a clinical study titled "A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1". The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
What is the current status of trial NCT03681184?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2018-11-27. Estimated completion is 2024-01-12.
What interventions are being tested in trial NCT03681184?
The interventions under investigation include: Placebo (DRUG), Lumasiran (DRUG).
Who is sponsoring clinical trial NCT03681184?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.